Tag Archives: Menarini

Business new tamfitronics --Achieved primary endpoint of LS mean reduction in LDL-C on top of maximally tolerated lipid modifying therapies at week 12 with statistically significant reduction (p<0.0001), which was sustained at week 52 (p<0.0001) -- -- Obicetrapib lowered LDL-C by 36.3% at week 12 and by 41.5% at week 52, compared to placebo -- -- Obicetrapib was well-tolerated; safety results comparable to placebo-- FLORENCE, Italy, July 29, 2024 /PRNewswire/ -- Menarini Group today announces positive topline data from the Phase 3 BROOKLYN clinical trial (NCT05425745) sponsored by NewAmsterdam Pharma Company N.V. ("NewAmsterdam"), a biopharmaceutical company which granted the Menarini Group an exclusive license to commercialize obicetrapib...